PanGenomic Health Announces Key Management Change
Vancouver, British Columbia, Canada – April 3, 2025 – PanGenomic Health Inc. has officially announced the resignation of Tammy Gillis from her position as Chief Financial Officer (CFO). In a strategic move, Gillis will transition to a role as a financial consultant, primarily to assist with the completion of the year-end audit process for the last fiscal year.
As part of this management change, Francisco Kent Carasquero, who is currently a director of the company, is to assume the role of CFO. Carasquero brings extensive experience in the financial services industry, having previously served as VP Finance at PanGenomic Health. His leadership experience includes a position as Executive Chair of FintechWerx International Software Services Inc. since 2023 and co-founding the payment services company, CPT Secure Inc, where he has been President since 2016.
Carasquero has also been instrumental in various initiatives through the fintech incubator, Looking Glass Media Limited, where he has served as both President and CFO since 2023. His academic background includes a Bachelor of Arts in Economics (Advanced) from the University of Manitoba.
PanGenomic Health is a precision health company dedicated to providing a self-care digital platform that delivers personalized, evidence-based information about natural treatments. Focused on supporting mental health, the company is registered as a British Columbia benefit company committed to promoting health and wellness through innovative technology platforms that tailor plant-based solutions to individual health profiles.
For inquiries, interested parties can contact Jerry Lai in Investor Relations at PanGenomic Health Inc., +1 778 743 4642, or via email at ir@pangenomic.com.
This press release contains forward-looking statements about the company’s future initiatives and potential outcomes. It is essential for stakeholders to recognize that these statements involve risks and uncertainties, and actual results may differ materially from those anticipated.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for its adequacy or accuracy.
Comments are closed